

Bangladesh

Population 2018

161 million

Estimates of TB burden ^o , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	357 (260–469)	221 (161–291)
HIV-positive TB incidence	0.73 (0.36–1.2)	0.45 (0.23–0.76)
MDR/RR-TB incidence ^{oo}	5.9 (3.2–9.6)	3.7 (2–5.9)
HIV-negative TB mortality	47 (30–67)	29 (18–42)
HIV-positive TB mortality	0.19 (0.094–0.32)	0.12 (0.06–0.2)

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	1.5% (0.9–2.3)
Previously treated cases	4.9% (3–7.9)

TB case notifications, 2018

Total new and relapse	267 143
- % tested with rapid diagnostics at time of diagnosis	18%
- % with known HIV status	1%
- % pulmonary	81%
- % bacteriologically confirmed ^{ooo}	72%
- % children aged 0–14 years	4%
- % women	41%
- % men	55%
Total cases notified	268 596

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	75% (57–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2018	13% (8–21)

TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	67	2%
- on antiretroviral therapy	63	94%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ^{ooo}	
- New cases	24%
- Previously treated cases	98%
Laboratory-confirmed cases*	MDR/RR-TB: 1 228, XDR-TB: 6
Patients started on treatment**	MDR/RR-TB: 1 147, XDR-TB: 6
MDR/RR-TB cases tested for resistance to second-line drugs	853

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2017	94%	242 640
Previously treated cases, excluding relapse, registered in 2017	86%	1 561
HIV-positive TB cases registered in 2017	67%	89
MDR/RR-TB cases started on second-line treatment in 2016	78%	918
XDR-TB cases started on second-line treatment in 2016	63%	8

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	43% (40–47)

TB financing, 2019

National TB budget (US\$ millions)	80
Funding source: 23% domestic, 63% international, 15% unfunded	

^o Ranges represent uncertainty intervals

^{oo} MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


^{ooo} Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




■ Total TB incidence
■ New and relapse TB cases notified
■ HIV-positive TB incidence

(Rate per 100 000 population per year)




■ HIV-negative TB mortality

Notified cases by age group and sex, 2018




■ Females ■ Males □ Incidence

Treatment success rate (%)



■ New and relapse
■ Retreatment, excluding relapse
■ HIV-positive ■ MDR/RR-TB ■ XDR-TB

Total budget (US\$ millions)



■ Unfunded
■ Funded internationally
■ Funded domestically